MEFLOQUINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mefloquine Hydrochloride, and when can generic versions of Mefloquine Hydrochloride launch?
Mefloquine Hydrochloride is a drug marketed by Barr, Hikma, Hikma Intl Pharms, Sandoz, and Us Army Walter Reed. and is included in five NDAs.
The generic ingredient in MEFLOQUINE HYDROCHLORIDE is mefloquine hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the mefloquine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mefloquine Hydrochloride
A generic version of MEFLOQUINE HYDROCHLORIDE was approved as mefloquine hydrochloride by BARR on December 29th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEFLOQUINE HYDROCHLORIDE?
- What are the global sales for MEFLOQUINE HYDROCHLORIDE?
- What is Average Wholesale Price for MEFLOQUINE HYDROCHLORIDE?
Summary for MEFLOQUINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 145 |
Clinical Trials: | 77 |
Patent Applications: | 1,434 |
DailyMed Link: | MEFLOQUINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MEFLOQUINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Prodia Diacro Laboratories P.T. | N/A |
National Research and Innovation Agency of Indonesia | N/A |
Universitas Padjadjaran | N/A |
Pharmacology for MEFLOQUINE HYDROCHLORIDE
Drug Class | Antimalarial |